Table 2 Clinical efficacy ASCs in immune-related skin diseases
Diseases | Study design | Efficacy | Transplant material | References |
|---|---|---|---|---|
SSc | Clinical trial (n = 6) | Significantly improved tightening of the skin without complications | ASCs | [129] |
Phase I trial (n = 12) | Significantly improved hand disability, pain, blood supply, and finger edema | SVF | [139] | |
Pilot study (n = 15) | Promotion of ulcer healing and increased capillaries in fingers | ASCs | [140] | |
Pilot study (n = 10) | Both ASCs and fat transplantations had significant effects, but the relative utility of each strategy could not be determined | ASCs / fat transplantation | [141] | |
Pilot study (n = 12) | Improved sclerosis, vascularization, and hand motion and strength | SVF | [142] | |
Case report (n = 1) | Improved blood flow and prevention of further amputation | SVF | [143] | |
Case report (n = 1) | Improved skin elasticity and vascularization | SVF (& PRP) | [144] | |
Clinical trial (n = 62) | Improved clinical symptoms in orofacial fibrosis | ASC-enriched lipotransfer | [145] | |
Clinical trial (n = 20) | Improvements in skin fibrosis, hand disability, Raynaud’s phenomenon, and active ulcers | SVF | [146] | |
Pilot study (n = 18) | Improved fat graft retention in the ASC‐assisted group to correct facial atrophy | ASC-assisted fat grafting | [147] | |
Phase II trial (n = 40) | Improved hand function in both groups over time, with no increased therapeutic efficacy of SVF relative to placebo | SVF( ±) | [134] | |
Randomized controlled trial (n = 88) | Trends of clinical improvements in patients with diffuse cutaneous SSc | ASCs | [130] | |
Psoriasis | Case report (n = 2) | Demonstrated safety and tolerability and decreased dependence on immunosuppressant drugs | ASCs | [148] |
Case report (n = 1) | Safely improved symptoms with a noticeable difference in skin quality and appearance | SVF | [131] | |
Case study (n = 1) | Completely regressed psoriasis and cleared inflammatory erythematous plaques | ASC-CM | [149] | |
Pilot study (n = 7) | Modality is safe to use and a potential therapeutic option | ASCs | [150] | |
SLE | Phase I trial (n = 9) | Established safety of the modality and potential efficacy in decreasing disease severity | ASCs | [151] |
AD | Case report (n = 2) | Marked improved erythematous facial lesions | ASC-Exos | [132] |